“Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials”, J of Skin, vol. 9, no. 6, p. s660, Nov. 2025, doi: 10.25251/1g590e41.